Author response to letter to the editor, (OSIN-D-25-00227) "From bisphosphonates to advanced therapies: a critical review of osteoporosis treatment strategies".
Gespeichert in:
| Titel: | Author response to letter to the editor, (OSIN-D-25-00227) "From bisphosphonates to advanced therapies: a critical review of osteoporosis treatment strategies". |
|---|---|
| Autoren: | Yukishima T; Department of Rheumatology, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Chuo-Ku, Hamamatsu, Shizuoka, 430-8558, Japan.; Kobayakawa Orthopaedics and Rheumatologic Clinic, 1969, Kuno, Fukuroi, Shizuoka, Japan., Ebina K; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. k-ebina@ort.med.osaka-u.ac.jp.; Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. k-ebina@ort.med.osaka-u.ac.jp., Etani Y; Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan., Noguchi T; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan., Ohmura SI; Department of Rheumatology, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Chuo-Ku, Hamamatsu, Shizuoka, 430-8558, Japan., Nakata K; Department of Health and Sport Sciences, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan., Okada S; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan., Kobayakawa T; Kobayakawa Orthopaedics and Rheumatologic Clinic, 1969, Kuno, Fukuroi, Shizuoka, Japan. |
| Quelle: | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2025 May; Vol. 36 (5), pp. 931-932. Date of Electronic Publication: 2025 Mar 19. |
| Publikationsart: | Letter |
| Sprache: | English |
| Info zur Zeitschrift: | Publisher: Springer International Country of Publication: England NLM ID: 9100105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2965 (Electronic) Linking ISSN: 0937941X NLM ISO Abbreviation: Osteoporos Int Subsets: In Process; MEDLINE |
| Imprint Name(s): | Original Publication: London, UK : Springer International, c1990- |
| Abstract: | Competing Interests: Declarations. Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Conflict of interest: KE has received research grants from Asahi Kasei, Eisai, and Teijin Pharma and speaker fees from Amgen, Asahi Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Ono Pharmaceutical, Pfizer, Taisho and UCB Japan. KE is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. YE received research grants and/or speaker fees from Asahi Kasei, Eisai, Eli Lilly, Ono Pharmaceuticals, and Taisho. YE is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. KN received a research grant from Astellas and supervises the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. TY, TN, SOhmura, SOkada, and TK declare that they have no conflicts of interest. Competing interest: We have no further competing interest. |
| References: | Yukishima T, Ebina K, Etani Y, Noguchi T, Ohmura SI, Nakata K, Okada S, Kobayakawa T (2025) Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study. Osteoporos Int. https://doi.org/10.1007/s00198-025-07386-4. Wadhwa H, Wu JY, Lee JS, Zygourakis CC (2023) Anabolic and antiresorptive osteoporosis treatment: trends, costs, and sequence in a commercially insured population, 2003–2021. JBMR Plus 7:e10800. (PMID: 10.1002/jbm4.108003780839810556263) Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM (2006) The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 166:1209–1217. (PMID: 10.1001/archinte.166.11.120916772249) Yang TL, Shen H, Liu A, Dong SS, Zhang L, Deng FY, Zhao Q, Deng HW (2020) A road map for understanding molecular and genetic determinants of osteoporosis. Nat Rev Endocrinol 16:91–103. (PMID: 10.1038/s41574-019-0282-731792439) Li N, Cornelissen D, Silverman S, Pinto D, Si L, Kremer I, Bours S, de Bot R, Boonen A, Evers S, van den Bergh J, Reginster JY, Hiligsmann M (2021) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics 39:181–209. (PMID: 10.1007/s40273-020-00965-933026634) Yu G, Tong S, Liu J, Wan Y, Wan M, Li S, You R (2023) A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis. Osteoporos Int 34:641–658. (PMID: 10.1007/s00198-022-06626-136527476) Hagino H, Tanaka K, Silverman S, McClung M, Gandra SR, Charokopou M, Adachi K, Johnson B, Stollenwerk B (2021) Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Osteoporos Int 32:2011–2021. (PMID: 10.1007/s00198-021-05927-133772328) van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102. (PMID: 10.1136/ard.2008.09277518677009) |
| Entry Date(s): | Date Created: 20250320 Latest Revision: 20250519 |
| Update Code: | 20250519 |
| DOI: | 10.1007/s00198-025-07466-5 |
| PMID: | 40108017 |
| Datenbank: | MEDLINE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Competing Interests: Declarations. Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Conflict of interest: KE has received research grants from Asahi Kasei, Eisai, and Teijin Pharma and speaker fees from Amgen, Asahi Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Ono Pharmaceutical, Pfizer, Taisho and UCB Japan. KE is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. YE received research grants and/or speaker fees from Asahi Kasei, Eisai, Eli Lilly, Ono Pharmaceuticals, and Taisho. YE is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. KN received a research grant from Astellas and supervises the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. TY, TN, SOhmura, SOkada, and TK declare that they have no conflicts of interest. Competing interest: We have no further competing interest. |
|---|---|
| ISSN: | 1433-2965 |
| DOI: | 10.1007/s00198-025-07466-5 |